XML 19 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets	6 Months Ended
Other Current Assets	Jun. 30, 2020
Other Current Assets
Other Current Assets	4.Other Current Assets As of June 30, 2020, other current assets included prepaid expenses of $1.4 million, comprised primarily of prepayments made for the Company's clinical trials for prexigebersen in AML, BP1002 in lymphoma and prexigebersen-A in solid tumors of $0.6 million, prepaid insurance of $0.5 million, prepayments for BP1003 manufacturing activities of $0.2 million and other prepaid expenses of $0.1 million. As of December 31, 2019, other current assets included prepaid expenses of $0.8 million, comprised primarily of prepayments made for the Company's clinical trials for prexigebersen in AML and CML of $0.6 million and prepaid insurance of $0.2 million.